ReviewImmunologic research2006
The CD94/NKG2 family of receptors: from molecules and cells to clinical relevance.
Review in Immunologic research, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 159 citations in OpenAlex.
- Polymorphisms within the human leucocyte antigen-E gene and their associations with susceptibility to rheumatoid arthritis as well as clinical outcome of anti-tumour necrosis factor therapy.Clinical and experimental immunology · 2015Trial
- Phase 1 multicenter study of the NKG2A targeting antibody S095029 as a single agent and in combination with anti-PD-1 in patients with advanced malignancies.Journal for immunotherapy of cancer · 2026Article
- Preclinical characterization of S095029, a novel clinical-stage Fc-attenuated NKG2A-blocking antibody for cancer immunotherapy.Frontiers in oncology · 2026Article
- Identification of Factors Contributing to Pathogenic Variability Among Lassa Virus Strains Using the Guinea Pig Model and Reverse Genetics.The Journal of infectious diseases · 2025Article
- Comprehensive Receptor Repertoire and Functional Analysis of Peripheral NK Cells in Soft Tissue Sarcoma Patients.Cancers · 2025Article
- NK Cells: A Powerful Squad Versus SARS-CoV-2.International journal of molecular sciences · 2025Review
- KLRD1 (CD94): A Prognostic Biomarker and Therapeutic Candidate in Head and Neck Squamous Cell Carcinoma.Journal of Cancer · 2025Article
- CD94 as a novel marker for immunophenotyping of leukemia and lymphoma in dogs.Frontiers in veterinary science · 2025Article
- Th17 and effector CD8 T cells relate to disease progression in amyotrophic lateral sclerosis: a case control study.Journal of neuroinflammation · 2024Article
- Characterization of tumor-infiltrating lymphocytes and their spatial distribution in triple-negative breast cancer.Breast cancer research : BCR · 2024Article
- Article
- CD94The European respiratory journal · 2024Article
- Unraveling factors responsible for pathogenic differences in Lassa virus strains.bioRxiv : the preprint server for biology · 2024Article
- NKG2AJournal for immunotherapy of cancer · 2024Article
- Multiple Protein Biomarkers and Different Treatment Strategies for Colorectal Carcinoma: A Comprehensive Prospective.Current medicinal chemistry · 2024Review
- FLAN: feature-wise latent additive neural models for biological applications.Briefings in bioinformatics · 2023Article
- Metabolic regulation of NK cell function: implications for immunotherapy.Immunometabolism (Cobham, Surrey) · 2023Review
- The complex HLA-E-nonapeptide in Behçet disease.Frontiers in immunology · 2023Article
- Membrane protein trafficking in the anti-tumor immune response: work of endosomal-lysosomal system.Cancer cell international · 2022Review
- Evolution and molecular interactions of major histocompatibility complex (MHC)-G, -E and -F genes.Cellular and molecular life sciences : CMLS · 2022Review
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Immune responses must be tightly regulated to avoid hyporesponsiveness on one hand or excessive inflammation and the development of autoimmunity (hyperresponsiveness) on the other hand. This balance is attained through the throttling of activating signals by inhibitory signals that ideally leads to an adequate immune response against an invader without excessive and extended inflammatory signals that promote the development of autoimmunity. The CD94/NKG2 family of receptors is composed of members with activating or inhibitory potential. These receptors are expressed predominantly on NK cells and a subset of CD8+ T cells, and they have been shown to play an important role in regulating responses against infected and tumorigenic cells. In this review, we discuss the current knowledge about this family of receptors, including ligand and receptor interaction, signaling, membrane dynamics, regulation of gene expression and their roles in disease regulation, infections, and cancer, and bone marrow transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.